ASH 2020: Results of a phase II study examining CAR T-cell therapy Axicabtagene Ciloleucel for first line treatment of diffuse large cell lymphoma.
Home / Resource Library / Interim results from ZUMA-12: Axi-cel as frontline treatment for high-risk LBCL